信邦製藥(002390.SZ):擬轉讓同德藥業29%股權予中醫院基金會及貴州智信
格隆匯7月15日丨信邦製藥(002390.SZ)公佈,按照蘇黔兩省關於加強中醫藥戰略合作協議精神,推進中醫藥產業發展,公司與江蘇省中醫院共同投資設立了貴州同德藥業有限公司(“同德藥業”)。為了鞏固和加強公司與江蘇省中醫院的合作,通過調整同德藥業的股權架構,公司擬將持有的同德藥業16%股權轉讓予江蘇省中醫院醫學發展醫療救助基金會(“中醫院基金會”)。
同時,為了進一步優化同德藥業的股權結構,充分調動公司經營管理團隊和同德藥業核心骨幹的積極性,促進員工與企業共同成長和發展,公司擬將持有的同德藥業13%股權轉讓予貴州智信企業管理諮詢合夥企業(有限合夥)(“貴州智信”)。
此次股權轉讓完成後,公司仍持有同德藥業51%股權,同德藥業仍為公司控股子公司,仍納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.